Clinical Trials
5 trialsNCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT04586335 2024-03-21
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
Phase 1 Terminated
NCT03386162 2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2 Terminated
NCT04330625 2022-11-08
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Duke University
Phase 1 Terminated
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated